immature platelets fraction
Diagnostic TestIPF-% and A-IPC using a reticulocyte detection channel CBC auto analyzer
NCT Number: NCT03232359
Immature platelet fraction is a non-invasive test of real time thrombopoiesis. High IPF% has been suggested as an indicator of thrombocytopenia due to rapid platelet consumption. IPF% is able to discriminate between patients with TTP/HUS or SPE/HELLP
Looking for future studies?
Notify Me20 year and older
Female
Observational
Thrombotic microangiopathy (TMA) syndromes are extraordinarily diverse. Thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS) are the two most well known, and are considered to be the most serious. TTP-HUS occurs more commonly in women and among women is commonly associated with pregnancy.
Nevertheless, there are other pregnancy conditions that may manifest with TMA, including preeclampsia, eclampsia, HELLP syndrome (hemolysis, elevated liver enzymes, and low platelet count), in addition to acute fatty liver of pregnancy, antiphospholipid syndrome, and systemic lupus erythematosis.
Assessment of immature platelets was introduced as a non-invasive test of real time thrombopoiesis. They are newly released in the circulation with a larger size & greater RNA content than mature platelets, and can be measured by automated haematology analyzer equipped with reticulocyte detection channel and described as immature platelet fraction (%-IPF) and immature platelet count (A-IPC).
A high %-IPF has been suggested as an indicator of thrombocytopenia due to rapid platelet consumption, while a low %-IPF is characteristic of bone marrow suppression states. %-IPF/A-IPF has the competency to be performed routinely and, therefore, can provide therapeutic and diagnostic feedback in the life threatening conditions.
The present study aimed to show the utility of estimating %-IPF and A-IPC using a reticulocyte detection channel CBC autoanalyzer as a simple reproducible blood analysis to be employed in the differential diagnosis of pregnancy-associated thrombotic microangiopathic conditions.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
IPF-% and A-IPC using a reticulocyte detection channel CBC auto analyzer
Time frame: 48 hours after delivery
clinical and laboratory changes after delivery
AYMAN ABDELKADER MOHAMED ABDELKADER
Other
Assessment of Immature Platelet Fraction in Pregnancy-Associated Thrombotic Microangiopathy
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03246542
Female Urogenital Diseases and Pregnancy Complications, HELLP Syndrome
View Trial DetailsNCT07263490
ART, Abruptio Placentae
Copenhagen, Denmark
View Trial DetailsNCT07430254
Female Urogenital Diseases and Pregnancy Complications, Hypertension, Pregnancy-Induced
Palo Alto, California, United States
View Trial DetailsNCT06580405
Female Urogenital Diseases and Pregnancy Complications, Hypertension, Pregnancy-Induced
View Trial Details